The ESH COVID-19 Task Force has generated a review on the relation of hypertension, the RAS, and risk of lower respiratory tract infections and lung injury. This work includes a critical appraisal of the molecular mechanisms linking the RAS to lung damage and the potential clinical impact of treatment with RAS blockers in patients with COVID-19.
As President and Secretary of the European Society of Hypertension (ESH) and on behalf of the Scientific Council of the ESH, we would like to send this message to you during this difficult time of the COVID-19 pandemic.
This very difficult and challenging time has not only raised profound questions about many aspects of our social life but has also brought many challenges in the field of medicine that go beyond the limits of management and care of COVID-19 patients.
In view of the unprecedented global situation related to COVID-19, we inform you that the ESH-ISH Joint Meeting in Glasgow, has been rescheduled to
April 11-14, 2021.
ESH-ISH 2021 is your meeting!
Study of the European Society of Hypertension on Blood Pressure Control in ESH Excellence Centres
dedicated to Professor Alberto Zanchetti.
The most important task of the European Society of Hypertension is to improve blood pressure treatment and increase blood pressure control, thus decreasing cardiovascular risk, premature cardiovascular and renal morbidity and mortality, with in addition a reduction of health-care costs.